Drug Trial Radar · NCT07846358
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Genfleet Therapeutics (Shanghai) Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase Ib/II clinical study evaluating GFH276 in combination with tislelizumab plus pemetrexed/platinum based regimen as first-line therapy in participants with locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) harboring RAS mutation or KRAS amplification.
Conditions
- RAS Mutation
- Non-small Cell Lung Cancer (NSCLC)
Interventions
GFH276Drug
Oral GFH276, administered at specified dose on schedule.
with or without TislelizumabDrug
Tislelizumab 200 mg, intravenous infusion, once every 3 weeks.or without Tislelizumab
PemetrexedDrug
Pemetrexed 500 mg/m², intravenous infusion, once every 3 weeks.
CisplatinDrug
Cisplatin 75 mg/m², intravenous infusion, once every 3 weeks.
CarboplatinDrug
Carboplatin at AUC=5, intravenous infusion, once every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib:Incidence of Dose-Limiting Toxicity (DLT) EventsTime frame: First 21 days
- Phase II:Objective Response Rate (ORR)Time frame: From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
- Phase Ib:Incidence and Severity of Adverse Events (AE) and Serious Adverse Events (SAE)Time frame: From the first dose until 30 days after the last dose, assessed up to 36 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.